Use of HIF-1a variants to accelerate wound healing

Details Use of HIF-1a variants to accelerate wound healing Use of HIF-1a variants to accelerate wound healing

2005-01-04

2005-01-04

Cochrane Carlson, Karen (Department: 1653)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S350000

Reexamination Certificate

active

06838430

ABSTRACT:
The present invention concerns the use of stable HIF-1α variants to accelerate wound healing. More particularly, the present invention provides a method of accelerating wound healing in a mammal comprising administering a stable variant of an HIF-1α polypeptide comprising an oxygen-dependent degradation domain. The stable HIF-1α variant preferably comprises an insertion, deletion or substitution in the oxygen-dependent degradation domain.

REFERENCES:
patent: 5604293 (1997-02-01), Fiddes et al.
patent: 5882914 (1999-03-01), Semenza
patent: 6124131 (2000-09-01), Semenza
patent: 6562799 (2003-05-01), Semenza
Arbeit, J. M. et al., “Progressive squamous epithelial neoplasta In K14-human papillomavirus type 16 transgenic mice,”Journal of Virology, vol. 68, No. 7, pp. 4358-4368 (1994).
Arbeit, J. M. et al., “Unpregulation of fibroblast growth factors and their receptors during multi-stage epidermal carcinogenesis in K14-HPV16 transgenic mice,”Oncogene, vol. 13, pp. 1847-1857 (1996).
Arbeit, J. M., “Transgenic models of epidermal neoplasta and multi-stage carcinogenesis,”Cancer Surveys, vol. 26, pp. 7-34 (1986).
Cardiology Network (Headlines): Sep. 26, 2001 8:07:24 PM, “Gene Therapy for Blood Vessel Growth to be Tested at University of Pittsburgh Medical Center,” World Wide Web Address: headlines.cardiologynet.org: pp. 1-2.
Carmeliet, P. et al., “Angiogenesis in cancer and other diseases,”Nature Cell Biology, vol. 407, pp. 249-257 (2000).
Detmar, M. et al., “Increased Microvascular Density and Enhanced Leukocyte Rolling and Adhesion in the Skin of VEGF Transgenic Mice,”The Journal of Investigative Dermatology, vol. 111, pp. 1-6 (1998).
Elson, D. A. et al., “Coordinate up-regulation of hypoxia inducible factor (HIF)-1α and HIF-1 target genes during multi-stage epidermal carcinogenesis and wound healing,”Cancer Research, vol. 60, pp. 6189-6195 (2000).
Feldser, D. et al., “Reciprocal positive regulation of hypoxia-inducible factor 1α and insulin-like growth factor 2,”Cancer Research, vol. 59, pp. 3915-3918 (1999).
Forsythe, J. A. et al., “Activation of Vascular Endothelial Growth Factor Gene Transcription by Hypoxia-Inducible Factor 1,”Molecular and Cellular Biology, vol. 16, No. 9, pp. 4604-4613 (1996).
Huang, L. E. et al., “Regulation and hypoxide-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway,”Proceedings of the National Academy of Sciences of the Unites States of America, vol. 95, pp. 7987-7992 (1998).
Iyer, N. V. et al., “Cellular and developmental control of O2homeostasis by hpoxia-inducible factor 1α,”Genes and Development, vol. 12, pp. 149-162 (1998).
Jettsch, M. et al., “Hyperplasia of Lympathic Vessels in VEGF-C Transgenic Mice,”Science, vol. 278, pp. 1423-1425 (1997).
Jiang B. H. et al., Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1.The Journal of Biolgical Chemistry, vol. 271, No. 30, pp. 17771-17778 (1996).
Jiang, B. H. et al., “Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2tension,”The American Journal of Physiology, vol. 271, pp. C1172-1180 (1996).
Jiang, B. H. et al., “Transactivation and Inhibitory Domains of Hypoxie-Inducible Factor 1α,”The Journal of Biological Chemistry, vol. 272, No. 31, pp. 19253-19280 (1997).
Kallio, P. J. et al., “Regulation of the Hypoxia-inducible Transcription Factor 1α by the Ubiquitin-Proteasome Pathway,”The Journal of Biological Chemistry, vol. 274, No. 10, pp. 6519-6525 (1999).
Larcher, F. et al., “VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development,”Oncogene, vol. 17, pp. 303-311 (1998).
Lee, S. H. et al., “Early expression of angiogenesis factors in acute myocardial ischemia and infarction,”The New England Journal of Medicine, vol. 342, No. 9, pp. 626-633 (2000).
Li, J. et al., “PR39, a peptide regulator of angiogenesis,”Nature Medicine, vol. 6, pp. 49-55 (2000).
Munz, B. et al., Overexpression of activin A in the skin of transgenic mice reveals new activities of activin in epidermal morphogenesis, dermal fibrosis and wound repair,The Embo Journal, vol. 18, No. 19, pp. 5205-5215 (1999).
Ratcliffe, P. J. et al., “Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression,”The Journal of Experimental Biology, vol. 201, pp. 1153-1162 (1998).
Ryan, H. E. et al., “HIF-1α is required for solid tumor formation and embryonic vascularization,”EMBO Journal, vol. 17, No. 11, pp. 3005-3015 (1998).
Semenza, G. L. et al., “Structural and functional analysis of hypoxia-inducible factor 1,”Kidney International, vol. 51, pp. 553-555 (1997).
Semenza, G. L. et al., “Transcriptional Regulation of Genes Encoding Glycolytic Enzymes by Hypoxia-inducible Factor 1,”The Journal of Biological Chemistry, vol. 289, No. 38, pp. 23757-23783 (1994).
Semenza, G. L., “Regulation of mammalian O2homeostasis by hypoxia-inducible factor 1,”Annual Review Cell and Development Biology, vol. 15, pp. 551-578 (1999).
Thurston, G. et al., “Leakage-Resistant Blood Vessels in Mice Transgenically Overexpressing Angiopoietin -1,”Science, vol. 288, pp. 2511-2514 (1999).
Vassar, R. et al., “Transgenic mice provide new insights into the role of TGF-α during epidermal development and differentiation,”Genes&Development, vol. 5, pp. 714-727 (1991).
Vincent, K. A. et al., “Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1α/VP16 hybid transcription factor,”Circulation, vol. 102, pp. 2255-2261 (2000).
Wang, G. L. et al., “Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2tension,”Proc. Natl. Acad. Sci. USA, vol. 92, pp. 5510-5514 (1995).
Wenger, R. H., “Mammalian oxygen sensing, signalling and gene regulation,”The Journal of Experimental Biology, vol. 203, pp. 1253-1263 (2000).
Zhong, H. et al., “Increased expression of hypoxia inducible factor-1α in rat and human prostate cancer,”Cancer Research, vol. 58, pp. 5280-5284 (1998).

Affiliated with

Also associated with

Rating

Use of HIF-1a variants to accelerate wound healing does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of HIF-1a variants to accelerate wound healing, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of HIF-1a variants to accelerate wound healing will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3373682